PIPELINE

CovX-Bodies have potential applications in a wide range of therapeutic areas. The company has generated a product pipeline and CovX scientists have validated CovX-Bodies against multiple targets in in vivo and in vitro models in a variety of therapeutic areas. CovX’s pipeline is initially focused on well-defined targets which inhibit tumor angiogenesis and modulate metabolic disorders.

CVX-045:  A THROMBOSPONDIN-1 MIMETIC COVX-BODY 

CVX-045 is a proprietary long-lasting Thrombospondin-1 ("TSP-1") mimetic CovX-Body that has shown compelling preclinical efficacy in multiple xenograft models. CVX-045 is a fusion protein composed of two TSP-1 mimetic peptides covalently bonded to CovX’s unique antibody scaffold via a proprietary linker. With an IND approval date of January 22, 2007, an open label dose escalation Phase 1 trial started at three U.S. centers in February 2007.

TSP-1 is a negative regulator of angiogenesis that has gained increasing attention as a therapeutic target within oncology. Exciting preclinical data for CovX’s TSP-1 mimetic therapeutic (CVX-045) provides a clear rationale for development in human clinical trials. CVX-045 has the potential to define and dominate a class of anti-angiogenic therapeutics outside of the VEGF arena, providing substantial benefits when applied to combination therapy and VEGF resistant tumors.  

CVX-060:  A SELECTIVE ANGIOPOIETIN-2 ANTAGONIST COVX-BODY

CVX-060 is a proprietary long-lasting CovX-Body that exquisitely binds Angiopoietin-2 ("Ang2") and has the potential
to be a best-of-class anti-angiogenic therapeutic.  CVX-060 is the fusion of two Ang2 sequestering peptides incorporating a linker with CovX’s proprietary antibody.  The IND for CVX-060 was approved on October 19, 2007 and
a Phase 1 clinical trial is expected to start enrolling in the fourth quarter 2007. 

There is a growing body of evidence that supports the role of Ang2 in angiogenesis.  Over-expression of Ang2 is known to assist in the mediation of angiogenesis and correlates with a poor prognosis in many solid tumors. There is also increasing evidence that Ang2 plays an important role in liquid tumors. CVX-060 has strong in vitro binding, in vivo efficacy, in vivo pharmacokinetic properties, and a high selectivity of Ang2 over Ang1.

CVX-060 substantially inhibits tumor growth and microvascular formation in xenograft models and is particularly effective when dosed in combination with either traditional cytotoxics or molecularly targeted agents such as Avastin™.

CVX-096: A LONG-ACTING GLP-1 MIMETIC COVX-BODY

CovX has completed extensive preclinical work on GLP-1 and exendin peptides using the CovX-Body technology. Our lead candidate, CVX-096, has demonstrated clear superiority via a 66 hour intravenous half life in rodents, high potency and excellent subcutaneous bioavailability.